{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:50:51Z","timestamp":1762098651288,"version":"3.40.5"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Describe atypical presentations of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Initial symptoms, diagnoses, and follow-up were recorded at the Austin Neuromuscular Center for 12 patients with nonclassical presentation of hATTR amyloidosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Common initial symptoms were hand and\/or feet sensory manifestations (83%), muscle weakness (58%), and, less frequently, gastrointestinal and orthostatic impairment and carpal tunnel syndrome. Initial diagnoses were polyneuropathy (83%) and\/or myopathy (25%). During follow-up, 10 patients (83%) developed cardiac symptoms (dyspnea, 67% and ankle edema, 17%), resulting in revised diagnoses of heart disease. Multisystem involvement raised suspicion of amyloidosis, which was confirmed by biopsy or nuclear scintigraphy, and genetic testing. All patients had polyneuropathy; 8 (67%) had cardiomyopathy-associated transthyretin mutations (V122I or T60A). Time from symptom onset to diagnosis was up to 10 years (median 5 years), during which patients' health deteriorated, although with recognition of disease signs\/symptoms the diagnosis of hATTR amyloidosis was made in approximately 2\u20136 months from presentation at our center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Increased awareness of the diverse initial hATTR amyloidosis symptoms could shorten time to diagnosis, enabling earlier treatment and improved patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000356","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T15:02:33Z","timestamp":1629903753000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Variable Presentation of Hereditary Transthyretin-Mediated Amyloidosis at a Single Center"],"prefix":"10.1097","volume":"23","author":[{"given":"Yessar","family":"Hussain","sequence":"first","affiliation":[{"name":"Austin Neuromuscular Center, University of Texas Dell Medical School, Austin, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11897-013-0182-4","article-title":"Novel drugs targeting transthyretin amyloidosis","volume":"11","author":"Hanna","year":"2014","journal-title":"Curr Heart Fail Rep."},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med."},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis."},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J Cardiovasc Transl Res."},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med."},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THASOS\u2014The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J."},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev."},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0025-6196(12)60388-7","article-title":"Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period","volume":"67","author":"Gertz","year":"1992","journal-title":"Mayo Clin Proc."},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J."},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","article-title":"Hereditary ATTR amyloidosis: a single-institution experience with 266 patients","volume":"22","author":"Swiecicki","year":"2015","journal-title":"Amyloid"},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis\u2014understanding the impact of management and disease progression","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201fRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst."},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","article-title":"Transthyretin cardiac amyloidoses in older North Americans","volume":"60","author":"Dharmarajan","year":"2012","journal-title":"J Am Geriatr Soc."},{"issue":"suppl 1","key":"R17-20250507","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ene.12842","article-title":"A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg","volume":"23","author":"Provitera","year":"2016","journal-title":"Eur J Neurol."},{"key":"R19-20250507","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail."},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Plante-Bordeneuve","year":"2007","journal-title":"Neurology"},{"key":"R23-20250507","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13506129.2019.1598358","article-title":"New sequence variants in patients affected by amyloidosis show transthyretin instability by isoelectric focusing","volume":"26","author":"Hinderhofer","year":"2019","journal-title":"Amyloid"},{"key":"R24-20250507","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Eftimov","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"R25-20250507","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11910-013-0435-3","article-title":"FAP neuropathy and emerging treatments","volume":"14","author":"Adams","year":"2014","journal-title":"Curr Neurol Neurosci Rep."},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/13506129.2017.1292902","article-title":"Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases","volume":"24","author":"Cruz","year":"2017","journal-title":"Amyloid"},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mus.26723","article-title":"Transthyretin amyloidosis: putting myopathy on the map","volume":"61","author":"Pinto","year":"2020","journal-title":"Muscle Nerve"},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/13506129.2011.623199","article-title":"Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis","volume":"18","author":"Ikeda","year":"2011","journal-title":"Amyloid"},{"key":"R30-20250507","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1529-8027.2011.00331.x","article-title":"Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients","volume":"16","author":"Cappellari","year":"2011","journal-title":"J Peripher Nerv Syst."},{"key":"R31-20250507","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","article-title":"Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy","volume":"260","author":"Dohrn","year":"2013","journal-title":"J Neurol."},{"key":"R32-20250507","first-page":"662","article-title":"Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy","volume":"14","author":"Leibou","year":"2012","journal-title":"Isr Med Assoc J."},{"key":"R33-20250507","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10072-012-1105-y","article-title":"TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients","volume":"34","author":"Luigetti","year":"2013","journal-title":"Neurol Sci."},{"issue":"suppl 1","key":"R34-20250507","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"R35-20250507","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:03:51Z","timestamp":1746651831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000356","relation":{},"ISSN":["1522-0443"],"issn-type":[{"type":"print","value":"1522-0443"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}